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Respiratory syncytial virus is the most important cause of viral lower respiratory illness in infants and children worldwide. By
the age of 2 years, nearly every child has become infected with respiratory syncytial virus and re-infections are common throughout
life. Most infections are mild and can be managed at home, but this virus causes serious diseases in preterm children, especially
those with bronchopulmonary dysplasia. Respiratory syncytial virus has also been recognized as an important pathogen in people
with immunossupressive and other underlying medical problems and institutionalizated elderly, causing thousands of hospitalizations
and deaths every year. The burden of these infections makes the development of vaccines for respiratory syncytial virus highly
desirable, but the insuccess of a respiratory syncytial virus formalin-inactivated vaccine hampered the progress in this field. To date,
there is no vaccine available for preventing respiratory syncytial virus infections, however, in the last years, there has been much
progress in the understanding of immunology and immunopathologic mechanisms of respiratory syncytial virus diseases, which has
allowed the development of new strategies for passive and active prophylaxis. In this article, the author presents a review about
novel approaches to the prevention of respiratory syncytial virus infections, such as: passive immunization with human polyclonal
intravenous immune globulin and humanized monoclonal antibodies (both already licensed for use in premature infants and children
with bronchopulmonary dysplasia), and many different vaccines that are potential candidates for active immunization against
respiratory syncytial virus.
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The Respiratory Syncytial Virus
(RSV) is considered the primary etio-
logic agent in acute respiratory infec-
tions in infants. Since its identification,
in the mid 50’s, several studies have
been conducted to develop effective
and safe vaccines against RSV. How-
ever, despite more than four decades of
intensive research, no effective vaccine
for the prevention of infections caused
by this agent has been developed up to
now. In the last few years, it was dem-
onstrated that passive immunization
with polyclonal and/or monoclonal
specific antibodies against RSV can ei-
ther prevent or attenuate the clinical
manifestations of RSV infections in
high-risk groups3,13,15,19,20,22,26,34,43,44. In
this paper, a short review on the pre-
vention of RSV infections through the
use of these pharmaceutical products is
presented, as well as a review on the
development of new vaccines against
RSV.
The agent – The RSV was first iso-
lated from chimpanzee’s coryza in
1955 and called the chimpanzee coryza
agent22,44. Soon after, the virus was iso-
lated from children with bronchiolitis
and recognized as the most common
cause of lower respiratory tract dis-
eases in children all over the world. In
1957, due to its ability to infect the res-
piratory tract cells and induce the for-
mation of syncytial giant cells in tissue
cultures, the virus was called respira-
tory syncytial virus44,51.
The RSV is a member of the
Paramyxoviridae family of the
Pneumovirus genus.34 There are two
primary antigenic groups (A and B)
and both present several strains.
The viral genoma, formed by a
single strand of RNA, codes for at least
10 distinct proteins, most of them struc-
tural proteins. There are at least two
non-structural proteins, the functions of
which are still unkonwn22,44,51. The
genoma, combined with the structural
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proteins forms the virus core or nucleo-
capsid, which is enclosed by an enve-
lope formed by different glycoproteins.
The glycoproteins F and G cross the
membrane and are the primary surface
antigens that are the target of the host
immune response. Protein F accounts
for the virus penetration into cells, and
for the cell membrane fusion which re-
sults in the formation of multinucleated
syncytial giant cells; the protein G ac-
counts for the virus binding to the
cells22,23,51. Whereas protein F undergoes
few changes, protein G presents greater
antigenic and genetic diversity in groups
A and B11,32,50 The subtype A seems to
be the most frequent, accounting for the
most severe cases12,30,56.
The aminoacid sequence of protein
G, of a virus of the same group which
circulates during an epidemic, can
reach 20%. Like the influenza virus,
the antigenic variations play a role in
RSV reinfections that occur over a life-
time; however, since RSV has a non-
segmented genoma, it presents less an-
tigenic variations than the influenza vi-
rus44.
RSV transmission occurs through
direct contact with secretions from in-
fected people or with contaminated
objects1,22. When infected, infants and
immunosuppressed individuals excrete
for a long time large quantities of RSV
in respiratory secretions. RSV infects
the respiratory tract mucosa and the
conjunctiva, and the symptoms appear
following a 2 to 8 day-incubation pe-
riod (most commonly 4 to 6 days)1,44.
Clinical Manifestations –RSV
replicates in the upper respiratory tract
cells, causing an inflammatory process,
which includes epithelium destruction,
edema and increased mucus produc-
tion. When the lower respiratory tract
is involved, bronchiolar hyperreactiv-
ity, frequently occurs, as well as the
changes already described 6,12,21-23,33.
Whereas most adolescents and
adults present mild disease with upper
respiratory tract symptoms (rhinorrhea
and cough) and low-grade fever, RSV
is considered the major etiologic agent
for lower respiratory tract infections,
such as bronchiolitis and pneumonia in
children under two years old; however,
mild and asymptomatic infections are
uncommon in infants. RSV is detected
in 40 to 90% of the bronchiolitis epi-
sodes and, during epidemic outbreaks,
accounts for more than 80% of the
cases. Half of the cases of pneumonia
occurring in children under two years
old are believed to be caused by RSV;
this agent is identified in 10 to 30% of
the cases of tracheobronchitis and, at
a lower rate (3%-10%) of the cases of
croup12,23,25,30,48.
Children under two months of age,
mainly preterm ones, can develop ap-
nea and atelectasis. In their first year
of life, preterm infants can present a
high risk of hospital readmission, par-
ticularly those with low weight at birth
and shorter gestational period1,51,61. Be-
sides preterm infants, children with
chronic pulmonary disturbances and
congenital heart disease present a
greater risk of lower respiratory tract
complications. The risk of hospital ad-
mission due to chronic respiratory dis-
ease was estimated in 12%, 17% and
28%, respectively, for preterm infants
without bronchopulmonary disease,
with mild bronchopulmonary disease
and moderate to severe bronchopulmo-
nary disease39.
RSV has been recognized as a ma-
jor cause of morbidity and mortality in
people presenting immune deficiency
associated with malignancies, chemo-
therapy or organ transplantation and
has accounted for up to 10% of hospi-
talizations for lower respiratory tract
infections in the elderly in the winter
season12,30,34,51.
RSV epidemics frequently occur in
a hospital environment, where the virus
is introduced by adults who generally
present either asymptomatic or mild in-
fection.1 When preterm infants as well
as other risk groups are infected, the
consequences can be devastating55. In a
study carried out by Langley et al.
(1997)29 in nine Canadian hospitals, 6%
of 1,516 hospitalized children presented
hospital-acquired RSV infections, fea-
tured by the agent identification and the
beginning of lower respiratory tract
symptoms 72 hours after hospitaliza-
tion. When compared with children with
community-acquired RSV infection,
those infected in the hospital environ-
ment had longer hospital stays (10 ver-
sus 5 days) and a higher rate of mortal-
ity (4.4% versus 0.42%).
RSV frequently causes bronchiolar
hyperreactivity both in children and in
adults11,21,22,33. Gross et al. (2000)21 have
recently demonstrated that the rate of
RSV infection in children under one
year of age admitted to hospital for
chronic obstructive respiratory disease
was 34.3% (74/216), whereas in the
control group, which involved 133
children hospitalized for other reasons,
RSV was detected in only 15% (20/
133). In this study, the children admit-
ted to hospital for CRD (chronic res-
piratory disease) or for other reasons
presented no differences regarding risk
factors for RSV infections, showing
that RSV plays a major role in obstruc-
tive respiratory disease in infants21.
In the last 20 years, a clear corre-
lation has been observed between se-
vere cases of bronchiolitis and the oc-
currence of changes in pulmonary
function in childhood. Several studies
have proven that, when compared with
the control groups, the children pre-
senting severe lower respiratory tract
impairment following RSV infection,
have, when they are six year old, re-
duced expiratory flow, even without
recurrent attacks of wheezing. How-
ever, it remains to be clarified if RSV
causes subsequent reduction of the pul-
monary function (cause-effect relation-
ship) or if individuals who already
present impaired pulmonary function
(atopia, bronchial hyperreactivity or
reduced airway diameter) have a
greater tendency to develop more se-
vere events after RSV infections
(causal relationship)33.
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Therapy for RSV Infections
The management of RSV infections
is basically supportive, including diet
care, oral hydration and ventilation sup-
port51. The antiviral therapy is restricted
to the use of aerosol ribavirine1,44.
Ribavirine is a virustatic drug that
should be used early, since the greatest
activity of RSV occurs up to three days
after the beginning of the lower respi-
ratory tract symptoms. Although it is a
low toxicity drug that has been shown
in several studies to be much more ef-
fective than placebo regarding the need
of oxygen supplementation, mechanical
ventilation and number of days of hos-
pitalization, controversies still remain
regarding its use, since this drug has not
shown to be effective in some studies.
There are doubts concerning the cost/
benefit ratio of its use and the effective-
ness of ribavirine in the prevention of
late pulmonary sequellae following
RSV infections30,32,47.
Epidemiology of RSV Infections
Humans are the unique sources of
infection. RSV is highly contagious
and its transmission occurs through di-
rect, or close, contact with contami-
nated secretions, droplets or fomites. It
is important to stress that the virus can
survive in contaminated hands for
more than a half hour, being common
the self-inoculation infections. The vi-
rus can survive for several hours in the
surface of contaminated objects1.
RSV presents a highly predictable
infection pattern, since the beginning
of outbreaks is anticipated by the in-
creased number of hospitalized infants
for bronchiolitis and/or pneumonia23.
In temperate climate countries, the
outbreaks occur in the winter season,
from the end of October up to the be-
ginning of the spring52 and, in tropical
climate countries, they occur during
the rainy season51.
It is estimated that more than 95%
of children are infected with RSV up
to the age of two, and more than half
are reinfected every year34. RSV infec-
tions and reinfections are common at
all ages, and a previous infection does
not protect against further infection,
even in the following years51,57.
About 15% to 22% of RSV in-
fected children under one year old
present lower respiratory tract involve-
ment and 0.5% to 2% require hospital-
ization34,57. The rate of mortality among
hospitalized children range from 0% to
5.2%44.
It is estimated that RSV causes ap-
proximately 84,000 to 144,000 hospi-
tal admissions of children under five
years old49, and 4,500 deaths each year
only in the United States26,31,43. In late
80’s, the annual cost of hospitalization
for RSV in the U.S. was estimated to
surpass 300 million dollars, without
considering the social burden caused
by work and school absenteeism.44,51
The outbreaks duration varies from
one year to another, but on average, the
outbreaks have a 22-week duration.
Both RSV groups (A and B) circulate
during the same epidemic period, but
the rate of episodes attributed to group
A and B virus varies from one year to
another, and from one site to another;
in addition, since there are different
strains of virus A and B, outbreaks
caused by genetically distinct strains
can follow an outbreak caused by a
single strain12,23,25,56.
Approximately, 50% of the chil-
dren are infected during RSV seasonal
outbreaks43. In Houston (USA), the rate
of infection was 68.8 per 100 children
under one year old and 82,6 per 100
children under two years old; in Swe-
den, seroepidemiological surveys re-
vealed that 87% of 18-month old chil-
dren, and almost all children over three
years old, have already been infected
with RSV20. Most infections occur be-
tween six weeks and six months of
age1,48. The mean age of the hospital-
ized children is 3 months, but among
the children seen at outpatient clinics
and private offices the mean age is
higher. From 100 children under one
year of age, 22 present lower respira-
tory tract disturbances, whereas from
100 children between one and two
years of age, 13 present lower respira-
tory tract impairment23. Although the
infections are much more common and
severe in young infants, many school
children present symptomatic infec-
tions caused by RSV51.
In Brazil, as in other countries,
RSV frequently circulates in the same
season as the influenza virus22,27,35,36.
Several studies have demonstrated that
RSV is the primary virus isolated from
children with severe respiratory dis-
ease, particularly in fall and winter sea-
sons 7,10,12,36. The infections are very
common in infants and the prevalence
in serum increases as they grow up.
Cox et al. (1998)7 observed in a
seroepidemiological survey that the
maternal antibodies against RSV per-
sist on average for 3.3 months. At 3
years old, 90% of children present an-
tibodies against RSV, whereas at 5
years old, such percentages reach
100% 7.
In São Paulo, it was observed that
RSV was the most frequently isolated
virus from children hospitalized for
acute respiratory disturbances, from
April to July 1996, in the Hospital
Universitário of São Paulo University.
From 126 children studied, respiratory
viruses were isolated from 71 (56.4%).
RSV was the most frequent virus iso-
lated from 66 cases (52.4% of the chil-
dren hospitalized for respiratory distur-
bances); this virus was detected in most
cases of bronchiolitis (84%) and in al-
most half of the pneumonia cases
(46%). The other viruses isolated were
the adenovirus (4) and the influenza vi-
rus (1). The median age of the children
from whose secretions the virus RSV
was isolated was 3 months, inferior to
that observed in the cases from which
other respiratory viruses were isolated
(13 months). When compared to other
respiratory viruses, RSV was associated
with a greater incidence of wheezing
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episodes (79% versus 33%). In the same
period, RSV was isolated from only two
of the 75 children hospitalized for non-
respiratory tract-related disturbances
(control group), suggesting that when
infected by RSV, the young children
normally present symptoms35.
Groups of Risk For Severe RSV In-
fections
RSV is responsible for the annual
outbreaks of bronchiolitis and pneumo-
nia which affect typically the children
under six months of age. In a study
conducted in the 70’s in Houston
(USA), Glezen et al. (1981)16 observed
that, among children from low-income
families, the risk of hospitalization for
infections caused by RSV was 5 out of
1,000 live born babies. More than 80%
of the hospitalized children were under
six months of age and the risk of hos-
pitalization was higher among those
who were born six months before RSV
seasonal outbreaks. The antibody titer
in the serum of 65 children with con-
firmed RSV infection was significantly
lower than that observed in 575 chil-
dren randomly selected, born in the
same period16.
In two large studies carried out in
Canada, it was observed that the
groups at higher risk of severe RSV in-
fections were the preterm infants, chil-
dren with bronchopulmonary dysplasia
(BPD) and those with congenital heart
disease (CHD)37.55. In both studies,
more than 25% of preterm infants hos-
pitalized for RSV infection required
ICU care and 15% to 18% required
ventilation support. The mortality rates
were also much higher in preterm in-
fants (0-3.3%), children with BPD
(3.5-5%) and CHD (3.4-5.2%), com-
pared to those observed in normal chil-
dren (<0.3%)44.
The major risk factors for severe
RSV infections are listed in table
19,13,16,29,43,55.
Studies involving children under
five years old from several developing
countries revealed that RSV was the
primary causative agent of lower res-
piratory tract infections, and that fac-
tors such as low social status, malnu-
trition, living in crowded environments
(two or more individuals sharing the
same bedroom, nursery attendance),
birth within the previous six months
from the beginning of RSV seasonal
outbreaks, the mothers’ low educa-
tional level and the domestic exposure
to cigarette smoke predispose to more
severe disease16,34,50,51.
In the developed countries the mor-
tality rates from RSV infections range
from 0.5% to 2%, but in the develop-
ing countries, these rates reach 7%. In
winter, up to 10% of the hospital ad-
missions of elderly people are due to
RSV infections and the rate of mortal-
ity achieves 10%, similar to the values
observed in the infections caused by
the influenza virus51.
Immune Response to RSV Infections
The humoral response is known to
play a significant role in the prevention
of RSV infections. Secretory IgA pro-
tects against infections of the mucosa
and the serum IgG partially protects
against the infections. However, the
antibodies do not provide full protec-
tion, and RSV reinfections continue to
occur over a lifetime 12,57.
The cell response seems to play an
essential role in the recovery from in-
fections, considering that individuals
with congenital or acquired impairment
of cell-mediated immunity present
more severe diseases and excrete the
virus for longer periods51. After natu-
ral infection, normal children respond
with the proliferation of cytotoxic lym-
phocytes specific against RSV; how-
ever, the cytotoxic lymphocytes can
both help the recovery and be respon-
sible for a more severe disease. In rats,
the cytotoxic lymphocytes CD8+ are
responsible for the elimination of the
virus from the lungs, but paradoxically,
seem to increase the severity of symp-
toms. The same can be observed in
helper T-lymphocytes CD4+, which
play a protective role and, at the same
time, can increase the disease severity.
There are two types of helper T-lym-
phocytes (Th1 and Th2), that are re-
sponsible for the production of differ-
ent cytokines: the lymphocytes Th1
produce interleukin 2 (IL-2), gamma
interferon and the tumor necrosis fac-
tor, whereas lymphocytes Th 2 produce
the interleukins IL-4, IL-5, IL-6 and
IL-318. The predominant stimulation of
lymphocytes Th2 are believed to be as-
sociated with more severe disease23.
Prevention of RSV Infections
The first vaccine against RSV was
developed in the 60’s. It was a forma-
lin-inactivated virus vaccine. Some
children immunized with this vaccine
developed a severe disease, followed
by sequelae after the natural infection
with RSV. Recent studies demonstrated
that the inactivated vaccine produced a
greater response of Th 2 lymphocytes,
whereas the live virus vaccines induced
a greater response of Th 123. The pre-
dominant stimulation of Th 2 response
Table 1 - Major risk factors for RSV infections.
- Under one year of age, especially under six months of age
- Prematurity
- Presence of chronic pulmonary disease, particularly bronchopulmonary dysplasia and cystic
fibrosis
- Presence of congenital heart disease, especially children with left-to-right shunt and pulmonary
hypertension
- Cell immune deficiency; malignancies, chemotherapy, spinal cord or solid organ transplants
- Hospital admission during RSV seasonal outbreaks
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and/or of cytotoxic lymphocytes is be-
lieved to have been responsible for the
occurrence of more severe disease in
infants vaccinated with this vaccine28,40-
42,45,50
.
Several problems should be taken
into account when considering the vac-
cination of children against RSV. The
major ones are listed in table 2.
 Although the immunologic charac-
teristics of RSV are being gradually re-
vealed, the first vaccine failure and the
difficulties in obtaining immunogenic
vaccines with low adverse reaction po-
tential in young infants led to studies
designed to evaluate the ways of pro-
tecting children against RSV through
passive immunization 2,23,34,44,51.
Passive immunization with policlonal
antibodies against RSV
Experimental studies conducted in
animals, and epidemiologic findings
obtained from full-term children re-
vealed that high antibody titers against
RSV’s protein F (1:200 to 1:400) pro-
vide protection against pulmonary in-
fection caused by this agent. Children
with high titers of transplacental-ac-
quired antibodies remain free from in-
fection for longer periods of time than
those presenting low antibody titers;
therefore, serum antibodies can pro-
vide partial protection against RSV in-
fection12,57.
Antibody titers against RSV above
100 reduce both the frequency and the
severity of respiratory tract infections in
children; the protection seems to be cor-
related with antibody titers against RSV.
In rats, neutralizing antibody titers
above 1:390 reduce by 99% the chance
of pulmonary infections, but higher ti-
ters (1:3.500) are needed for a similar
reduction in nasal symptoms to occur;
therefore, the neutralizing antibodies
protect better against lower than upper
respiratory tract infections44.
Based on these results, the role
played by human immunoglobulin in
the protection against RSV has been
investigated since the beginning of the
90’s. Although safe, the monthly infu-
sion of high doses (750 mg/kg) of nor-
mal human immunoglobulin in preterm
neonates contains low antibody titers
against RSV (only 1:87) and provides
no protection against RSV infections19.
Therefore, a specific immunoglobulin
containing high antibody titers against
RSV (RSV-IGIV) has been developed.
The specific immunoglobulin (res-
piratory syncytial virus immunoglobu-
lin – RSV-IGIV, Respigam) contains
approximately six times the antibody
titers of the normal human immunoglo-
bulin and is 10 times more potent in the
reduction of RSV titers after experi-
mental infections in rats. In vitro stud-
ies demonstrated that RSV-IGIV can
neutralize a number of groups A and
B RSV strains3,34,43.
The first multicenter study to dem-
onstrate the effective use of the
policlonal immunoglobulin specific
against RSV was sponsored by the Na-
tional Institute of Allergy and Infec-
tious Diseases (NIAID) and published
by Groothuis et al. (1993).19 In this
study, 249 children under 48 months of
age (mean age = 8 months) presenting
bronchopulmonary dysplasia due to
prematurity (n= 102), congenital heart
disease (n= 87) or preterm infants un-
der 35 week-gestational age and below
six-month chronological age (n= 60)
were evaluated. The children were di-
vided into three groups: A) a group of
81 children received five monthly 750
mg/kg injections of RSV-IGIV immu-
noglobulin (high dose group = 15 ml/
kg); B) a group of 79 children received
150 mg/kg of RSV-IGIV (low dose
group = 3 ml/kg) and group C, com-
posed of 89 children who received pla-
cebo in five monthly injections. Dur-
ing the follow-up period, 64 episodes
of RSV infections were confirmed: 19
in group A (high dose of RSV-IGIV),
16 in group B (low dose of RSV-IGIV)
and 29 in group C (control). In group
A (high doses of RSV-IGIV) a lower
rate of lower respiratory tract infections
(7 versus 20, compared to the control
group, p=0.01), a lower rate of hospi-
tal admissions (6 versus 18 in the con-
trol group), shorter hospital stays (43
versus 128 days, p=0.02), shorter stays
in intensive care units and lower use of
ribavirine (p= 0.05) were observed. In
group B (low dose of RSV-IGIV), only
a reduction in the number of days of
hospitalization in intensive care units
was observed, no significant effect on
the reduction of lower respiratory tract
infections rate being detected.
The adverse effects associated with
the use of RSV-IGIV were rare (3%)
and mild in most cases. Five children
Table 2 - Major problems associated with the active immunization against RSV.
Problem Comments
1. Most infections occur in infants - There are technical and ethical obstacles
involved in the vaccination of young
infants or pregnant women
2. RSV has a short period of incubation - The vaccines should stimulate both the
serum and the mucosa immunity
3. Glycoproteins F and G are the primary - Glycoproteins are poor immunogenic
antigens responsible for the immunity antigens, particularly in infants
4. There are several strains of RSV - The vaccines should provide protection
against several strains of Types A and B
5. Natural infection does not provide - Effective vaccines that can provide greater
full protection protection than that obtained after the
natural infection will hardly be developed.
6. Children who have received the inactivated - All the pathophysiologic mechanisms and
vaccine presented more severe disease the immune response to RSV are still
when infected with RSV. unknown.
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presented fluid overload associated to
RSV-IGIV infusion, but all of them
showed a good response to the use of
diuretics. Eight children presented a
slight reduction in oxygen saturation
and six presented fever. Only a more
severe reaction was observed – a 17-
month old infant developed high-grade
fever (T= 40.6oC) after the second dose
of RSV-IGIV, followed by increased
respiratory distress. This child pre-
sented severe BPD and evoluted to pro-
gressive fall in ventilation function,
dying three months later. In total, six
children died during the follow-up pe-
riod, five of them presenting congeni-
tal heart disease and, in three cases,
death was directly associated to the
surgical intervention. In none of the
cases the death was directly associated
to the use of RSV-IGIV.
This study showed that, although the
total number of RSV infections has not
been significantly reduced in groups 1
and 2, the use of high doses of RSV-
IGIV reduced the disease severity, de-
creasing in up to 63% the rate and du-
ration of hospital stays for RSV, and, in
up to 97%, the number of days in ICU19.
Despite the good results observed in this
study, the Food and Drug Administra-
tion (FDA) did not approve of the li-
cense for RSV-IGIV, due to potential
immunoglobulin adverse events and the
need for a better study design to evalu-
ate its effectiveness in different groups57.
In order to better evaluate the safety
and effectiveness of high-doses of
RSV-IGIV among children with bron-
chopulmonary dysplasia and/or prema-
turity status, a new study was con-
ducted (Prevent Study Group) in 54
centers in the United States, in which
510 children with bronchopulmonary
dysplasia and/or prematurity status
were included and randomly assigned
to treatment with high-dose RSV-IGIV
(750 mg/kg) or placebo (1% albumin)
in five monthly intravenous infusions,
during the 1994-1995 RSV season.
The children were followed over 30
days after the last infusion. In the
group receiving RSV-IGIV, 20 RSV
infections (8%) were observed,
whereas in the placebo group, 35
(13.5%) were confirmed, with a 41%
reduction in the incidence of hospital-
izations for RSV in the treated group.
For each 100 children treated with
RSV-IGIV, a 53% reduction in the
number of days of hospitalization was
observed in the presence of moderate
to severe lower respiratory tract infec-
tions and, in the presence of lower res-
piratory tract infections of any sever-
ity, this reduction achieved 38%43.
The children presented good toler-
ability to high doses of RSV-IGIV (15
ml/kg). However, in 1.8% of the cases,
the infusion had to be discontinued due
to volume overload. In total, 8.4% of the
children (1% preterm and 13% with
BPD) received diuretics in, at least, one
infusion, but, in most cases, it was im-
possible to specify if its use was preven-
tive or therapeutic. Three children in-
cluded in the RSV-IGIV-treated group
presented an increase in the number of
CSF cells (20 cells or below); one of
them was presumptively diagnosed with
enteroviral meningitis (nasopharinx-
isolated enterovirus), the other was
treated for herpes simplex and presented
an improvement and the third one was
diagnosed during an investigation for
sepsis. Fever was observed in 6% of the
treated group and in 2% of the placebo
group. One of the most interesting as-
pects of this study was the finding that
the children receiving RSV-IGIV pre-
sented a lower incidence of skin rash
(38% versus 48%) and acute otitis me-
dia (27% versus 43%), when compared
to the placebo group43.
The role of RSV-IGIV prophylaxis
in children with congenital heart disease
is controversial. One study conducted
by Simões et al. (1998)50 evaluated the
effectiveness and safety of this
policlonal immunoglobulin in 416 chil-
dren with congenital heart disease; 202
received monthly injections of RSV-
IGIV and 214 served as a control group.
A tendency towards a reduction in the
rates and duration of hospital stays was
observed among the treated children.
However, the children presenting con-
genital cyanotic heart disease and
treated with the specific immunoglobu-
lin presented a greater number of cyano-
sis episodes and higher rates of compli-
cations following cardiac surgery when
compared with the control group.
In none of the studies in which the
use of the specific immunoglobulin
against RSV has been evaluated, it was
possible to demonstrate a significant
reduction in the mortality rates in the
treated groups, when compared to non-
treated groups44, but since the safety
and effectiveness of RSV-IGIV in re-
ducing RSV infection complications
has been demonstrated, this product
was licensed by the USA FDA in Janu-
ary 18, 19961,2,34,57.
The use of RSV-IGIV: cost/benefit
ratio
The use of RSV-IGIV is approved
for children under two years of age
who were born with less than 36 weeks
of gestation, or who present bronchop-
ulmonary dysplasia. However, for each
hospitalization for RSV prevented, it is
estimated that 16 preterm infants (12
preterm with BPD or 63 preterm with-
out BPD) should receive prophy-
laxis44,46,50.
In the U.S., the cost of five doses
of RSV-IGIV ranges from US$3,200 to
US$13.988 for infants weighting 1,2 to
10 kg at the beginning of treatment39,52.
It is estimated that US$ 1,4 billion is
necessary to administer RSV-IGIV to
all preterm infants. Due to its high cost,
it is believed that the use of RSV-IGIV
should be reserved only to high-risk
groups, such as those with BPD requir-
ing oxygen supplementation or neo-
nates under 32 weeks of gestation, spe-
cially those born close to RSV sea-
son44. A recent study demonstrated that
over the two years that followed the
beginning of RSV-IGIV use for
preterm infants under 32 weeks of ges-
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tation, a significant reduction in the
disease-related costs (>60%) has been
observed, when compared to the two
years that preceded the licensing of this
immune biologic product3.
Besides the high cost, the use of
RSV-IGIV carries the following pro-
blems: it requires the use of a venous
access route, hospitalization for several
hours for drug infusion, difficulties re-
garding product availability (blood de-
rivative), potential for severe adverse
events (volume overload, aseptic men-
ingitis, anaphylactic reactions in people
with IgA deficiency and cyanosis epi-
sodes) and possible interference with
the immunogenicity of measles,
mumps, rubella and varicella live vac-
cines, which should be postponed for
9 to 10 months1,13,34,52. For these rea-
sons, other forms of infection preven-
tion have been investigated, such as the
use of monoclonal antibodies11,13,20,28-30
or new vaccines4,5,8,13-15,20,23,28,40-42,44,59.
Passive immunization against RSV
with monoclonal antibodies
Since the nasal mucosa is the ma-
jor route for the RSV, the topical use
of IgA-type antibodies was thought to
protect against the infection. In mon-
keys, the topical use of murine IgA
monoclonal antibodies targeting RSV
protein F reduced the RSV replication,
but in children, a placebo-controlled
study did not demonstrate a good ef-
fectiveness of these antibodies, despite
the small size of the study34.
In experimental animals, the
parenteral use of monoclonal antibod-
ies can lower in up to 99% the rate of
RSV infections. Two large studies have
been carried out with monoclonal an-
tibodies, targeting RSV glycoprotein F,
given to children through the parenteral
route. In a first study, a monoclonal
antibody, produced by Smith Kline
Beecham (SB 209763) was used in 791
children from 93 centers. The children
were randomly assigned to receive
monthly injections of 10 mg/kg of the
drug or placebo. The results of this
study were disappointing, probably due
to the low dose or low antiviral activity
of the antibodies34.
In a second study, the parenteral
use of humanized monoclonal anti-
bodies produced by MedImmune
(MEDI-493, palivizumab, Synagis)
showed good results in the prevention
of RSV severe infections26.
Palivizumab contains monoclonal
antibodies that bind to RSV surface pro-
tein F and exert high activity against
group A and B virus; it is produced by
genetic engineering techniques (fusion
of murine myeloma cell with T lympho-
cytes in BALB/c rats immunized with
the RSV human A2 strain). In order to
reduce the potential sensibilization that
murine antibodies could cause in hu-
mans, the nucleotide sequence that
codes for the antibody binding site con-
tains 95% of the aminoacid sequence
found in human antibodies and only 5%
of that found in murines. This is ob-
tained through the insertion of the gene
that codes for a human IgG1 subclass
molecule in the genoma of the cell line,
which produces the monoclonal anti-
bodies. The murine aminoacid sequence
is restricted almost exclusively to the
combination sites of the antibody with
the virus, which decreases the chances
for an individual to present hypersensi-
tivity reactions to the product, due to the
production of anti-idiotypical anti-
bodies13,26.
The Impact-RSV Study Group was
the first large study conducted to deter-
mine the safety and effectiveness of
palivizumab7. This study was carried out
in 1996-1997 in 139 centers from the
U.S. (n=119), Canada (n=9) and the
United Kingdom (n=11) and included
1,502 preterm infants (35 weeks and <6
months of age) or children under two
years of age with bronchopulmonary
dysplasia requiring continuous medical
treatment (i.e., oxygen supplementation,
steroids, bronchodilators or diuretics
within the last six months). The children
were randomly assigned to receive
monoclonal antibody (15 mg/kg) or
matched placebo intramuscularly in the
form of five monthly injections and were
followed for 150 days (up to 30 days af-
ter the last injection), being evaluated the
hospitalization rate, the number of days
of hospitalization, the need for oxygen
supplementation, the disease severity, the
number of days of hospitalization in in-
tensive care unit and the need of me-
chanical ventilation. More than 93% of
the children completed the protocol. The
use of palivizumab reduced by 55% the
hospitalizations for RSV (10.6% in the
placebo group versus 4.8% in the mono-
clonal antibody-treated group;
p=0.00004); preterm infants without
BPD presented a 78% reduction in the
rate of hospitalizations (8.1% versus
1.8%; p=0,001) and children with BPD
presented a 39% reduction (12.8% ver-
sus 7.9%; p=0.038). For each group of
100 children followed, it was observed
that the treatment with palivizumab re-
duced significantly the number of days
of hospitalization (62,6 days in the pla-
cebo group versus 36,4 in the
palivizumab group), the number of days
with increased need of oxygen supple-
mentation (50,6 days in the placebo
group versus 30,3 days in the
palivizumab group) and the number of
days with more severe pictures (severity
score 3: 47,7 days in the placebo group
versus 29,6 days in the palivizumab
group). The drug was well tolerated with
few adverse events occurring at a fre-
quency not significantly superior to that
observed in the placebo group. Local re-
actions occurred, such as mild erythema
(1.8% in the placebo group versus 2.7%
in the treated group), being observed a
slight increase in hepatic enzymes in
both groups (AST: 1.6% in the placebo
group versus 3.6% for palivizumab; ALT:
2.0% in the placebo group versus 2.3%
for palivizumab). Only 0.3% of the chil-
dren treated discontinued therapy26.
Comparing the results of this study
with the results obtained with the use
of the specific immunoglobulin (RSV-
IGIV), it was observed that the use of
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monoclonal antibodies is safer and
more convenient for the child13.
Whereas the use of high doses of RSV-
IGIV requires venous access and sev-
eral hours of infusion (15 ml/kg dose),
the use of monoclonal antibodies is
easier through the intramuscular route.
In addition, monoclonal antibodies
seem to be more effective in the reduc-
tion of hospitalization rates in children
infected with RSV. The reduction of
hospitalization rates obtained with
palivizumab and RSV-IGIV were, re-
spectively, 55% (95% CI: 38%-72%)
and 41% (95% CI: 10%-72%)26.
The size of the Impact trial allowed
for the evaluation of the efficacy of
monoclonal antibodies in different
groups, stratified according to the birth
weight, gestational age and the presence
of BPD. Significant reductions in hos-
pitalizations were observed in the fol-
lowing groups: children over 5 kg (51%,
p=0.014) and children  5 kg (57%,
p=0.001); children under 32-weeks
(47%; p=0.03) and 32-to-35 week ges-
tational age (80%, p=0.002). The results
were similar in all study centers (USA,
Canada and United Kingdom)26.
Palivizumab (Synagis) was licensed
in the United States in June 1998 and
has been available in several countries
since 199951. In Brazil, it is commer-
cialized by Abbott and distributed in
packages containing one 100 mg vial
of lyophilized powder, which should
be stored at 2oC to 8oC (do not freeze).
According to the manufacturer,
palivzumab should be gently reconsti-
tuted before use with sterile water and
homogenized with slow movements
(do not shake the vial). After reconsti-
tution, it should be allowed to rest at
room temperature for at least 20 min-
utes, until the solution becomes clear.
It should be used within six hours.
Despite the proven efficacy of
palivizumab in 32 to 35 week-gestation
children without bronchopulmonary
disease (82% reduction in hospitaliza-
tion rates among 335 children born be-
tween the 32nd and the 35th gestational
weeks without chronic pulmonary dis-
ease)26, it should be considered that
RSV infections rarely are fatal, even in
high-risk groups, if the children receive
proper medical care, and that the cost
of the drug is still too high to be rec-
ommended for all preterm infants un-
der 35-week gestation.
It is estimated that 288,000 babies
under 36-week gestation and approxi-
mately 80,000 under 32-week gestation
are born each year in the United States
alone34,44. Since there are no studies on
the cost/benefit ratio of palivizumab,
the cost of the drug is high and few ex-
periments exist on this drug, the AAP
does not recommend it for all children
under 35-week gestation. In the United
States, the cost of a 100 mg vial of
palivizumab is US$ 900; the cost of the
therapy involving five doses of the
product for a child under 3 kg weight
ranges from US$ 2,250 to US$4,500,
depending on whether the product can
be or not shared with other cli-
ents13,34,44,51,57. It is estimated that 17,2
patients need to be treated with the
product to prevent hospitalization and
that the cost of each hospitalization
prevented would achieve approxi-
mately US$77,000. This cost is 10
times greater than the cost of hospital-
ization for non-treated individuals44.
Therefore, it is suggested that the
prophylactic use of monoclonal anti-
bodies, as well as RSV-IGIV, be re-
served for higher risk groups and that,
for 32 to 35-week gestation children,
these drugs are indicated only if the
child presents concomitant problems
that also predispose for respiratory
complications such as, neurologic dis-
turbance, promiscuity (a large number
of people sharing the same bedroom,
many siblings, nursery or day-care cen-
ter attendance), domestic exposure to
cigarette smoke or a scheduled cardiac
surgery. In addition, the availability
and access to hospital centers for the
treatment of severe respiratory diseases
should be taken into consideration.
Despite these recommendations, it is
essential to remember that most chil-
dren presenting such prerequisites will
not have severe RSV disease and that
the costs and logistic difficulties to treat
these children can neutralize the pos-
sible benefits1,3,13,44,51,57.
Since 1997, the American Academy
of Pediatrics has recommended the use
of RSV-IGIV for children under two
years of age with previous history of
chronic bronchopulmonary disease,
who required oxygen supplementation
within the previous six months from
RSV season1. After palivizumab regis-
tration, the use of monoclonal antibod-
ies (palivizumab) has been preferred.
The advantages of the use of mono-
clonal antibodies are summarized in
table 3.
Table 3 - Advantages and disadvantages of the use of monoclonal antibodies when compared to the specific immunoglobulin.
Characteristics Monoclonal antibodies Specific immunoglobulin
Antibody titers against RSV Very high 10 to 50 times lower when compared to
monoclonal antibodies
Safety Comparable to placebo Risk of volume overload
Administration IM, more convenient and rapid IV, slow and more expensive
Interference with live virus vaccines None Possible. It is recommended to wait up to 9
months to administer live virus vaccines
Cost High (10% lower than that of RSV-IGIV) High
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Considering that the use of mono-
clonal antibodies is safer and more
convenient for the child than the RSV-
IGIV, its use should be considered in
the following cases34:
1. Children under 24 months of age
with chronic pulmonary disease,
who required treatment in the last
six months;
2. Infants born between the 28th and
the 32nd week of gestation, without
chronic pulmonary disease, and un-
der six months of age at the begin-
ning of winter;
3. Infants born with less than 28 weeks
of gestation, without chronic pulmo-
nary disease and under one year of
age at the beginning of RSV season;
4. Infants born with 32 to 35 weeks of
gestation without chronic pulmo-
nary disease, who are under six
months of age at the beginning of
RSV season presenting concomi-
tant risk factors (crowded environ-
ments, siblings at school age, do-
mestic exposure to cigarette smoke,
multiple parities).
5. Prophylaxis with palivizumab is
not recommended for children with
congenital heart disease, unless the
child is included in the groups men-
tioned above, and if it presents he-
modynamically compensated le-
sions, such as patent ductus arterio-
sus or small septal defects.
6. Neither the specific immunoglobu-
lin (RSV-IGIV) nor the monoclonal
antibodies (palivizumab) are indi-
cated for the treatment of RSV in-
fections.
Despite the advantages of
palivizumab, there is, up to now, no study
comparing directly the risks, benefits and
costs derived from the use of monoclonal
antibodies with specific immunoglobulin.
In addition, since RSV-IGIV provides
protection against other viral respiratory
diseases, in some situations its use can be
preferred in certain groups of risk, such
as children who have already been re-
ceiving replacement therapy with intra-
venous immunoglobulin for the treat-
ment of immune deficiency, including
HIV infection1,13,34,51.
Passive immunoprophylaxis in im-
mune deficient individuals
The safety and effectiveness of pas-
sive immune prophylaxis against RSV
is being clinically evaluated in indi-
viduals with cellular immune defi-
ciency, particularly those undergoing
organ transplants or presenting more
severe illnesses. HIV-infected children,
although excreting RSV for prolonged
periods, do not seem to present more
severe illnesses and the routine use of
passive prophylaxis with specific im-
munoglobulin, or with palivizumab, is
not recommended. The indication for
prophylaxis against RSV has been
evaluated in children with cystic fibro-
sis and asthma, but, up to now, the risks
and benefits derived from the use of
passive immune prophylaxis are not
clear in such situations34.
New perspectives for the active im-
munization against RSV
Besides specific immunoglobulin
and monoclonal antibodies for nasal
and intramuscular use, several new
vaccines containing RSV-attenuated
strains (cold adapted, temperature sen-
sitive, developed through recombinant
technology), vaccines containing puri-
fied proteins (developed through re-
combinant genetic engineering or live-
vector produced), synthetic peptide
vaccines and DNA vaccines are cur-
rently under investigation4,5,8,13-
15,17,18,20,23,28,32,40-42,54,59,60
.
Attenuated live virus vaccines – In
the 70’s, Wright et al. (1976)59 tested a
temperature-sensitive (ts) intranasal vac-
cine containing attenuated RSV in
twenty-five children aged 11 to 19
months, in a randomized and controlled
trial (controlled, double-blind protocol).
From the 25 children receiving this vac-
cine (100 TCID50), eight were infected
with the vaccinal strain, as confirmed by
viral shedding or higher serum antibod-
ies; however, the rate of infection with
the wild virus was comparable to the
groups of children receiving the nasal
vaccine or placebo. Despite having
failed to provide protection to vacci-
nated children, unlike the inactivated
vaccine, this nasal, live, attenuated vi-
rus vaccine showed to be safe, causing
no increase in the disease severity in the
vaccinated children exposed to and in-
fected with the wild virus in the follow-
ing year. Therefore, the attenuated virus
vaccine becomes the standard for the
development of new experimental vac-
cines59. One of the greatest difficulties
in the development of vaccines against
RSV is to obtain strains properly bal-
anced in terms of immunogenicity, sta-
bility and safety. Some attenuated vac-
cines have shown a low level of immu-
nogenicity while others have shown to
be very unstable 8,31.
Since the temperature-sensitive at-
tenuated virus vaccines are not ad-
equately immunogenic, new vaccines
have been recently tested in which the
virus attenuation is obtained through
other techniques, such as expression of
interleukins and are presently undergo-
ing clinical trials in animals5.
Vaccines containing protein F puri-
fied
Protein F is the major antigen re-
sponsible for the production of antibod-
ies against RSV subtypes A and B;
therefore, vaccines containing the puri-
fied protein F, obtained through genetic
engineering techniques, seem to be
highly promising in the prevention of
diseases caused by this agent. Groothuis
et al. (1998)20 administered one dose of
the PFP-2 vaccine against RSV to 10
children with bronchopulmonary dys-
plasia and the influenza vaccine to 9
children; 90% (9/10) of the children
who received the PFP-2 vaccine pre-
sented a (four-fold) increase in serum
antibody titers against RSV versus 0/11
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in those receiving the influenza vaccine.
After one year, it was observed that both
groups presented similar antibody titers
against protein F and neutralizing anti-
bodies against RSV. However, whereas
in the control group half of the children
(6/11) were hospitalized for RSV respi-
ratory disease, in the vaccinated group,
the hospitalization rate for the same rea-
son was only 10% (1/10; p=0.06). The
PFP-2 vaccine showed to be safe and
immunogenic in children with BPD20.
Piedra et al. (1996)41 administered
the PFP-2 vaccine against RSV to 17
children with cystic fibrosis (median
age=4,5 years) and other 17 children
(median age= 5,8 years) received pla-
cebo. While the vaccine has failed to
fully protect against RSV, a significant
reduction (P=0.01) in the number of
lower respiratory tract infection epi-
sodes was observed in the vaccinated
group (0,8) when compared to the con-
trol group (2,1), as well as a significant
reduction in the days of disease dura-
tion (30,5 versus 67) in the group re-
ceiving the PFP-2 vaccine. The local
and systemic reactions to this vaccine
were mild in nature, being observed no
increase in the disease severity in the
reinfected children.
In the following year, the same
group of investigators revaccinated the
children with the PFP-2 vaccine and
demonstrated that the revaccination
was quite safe, causing no increase in
the adverse events42.
CONCLUSIONS
Preliminary studies using several
vaccines against RSV, both in experi-
mental animals and humans, seem to
provide promising results9,11,19,17. How-
ever, it should be stressed that natural
infection does not fully protect against
infection and reinfection and, since the
immunological factors related to RSV
protection have not been fully clarified,
it is unlike that an effective vaccine that
can provide a high level of protection
against this agent can be developed on
a short-term basis. Theoretically, the
vaccination of pregnant women could
benefit neonates. However, the vaccine
safety issues in this group make it dif-
ficult to conduct studies on this new
perspective for the prevention of severe
RSV diseases18,34.
Concluding, it is worth remember-
ing that the most effective way to con-
trol nosocomial RSV infections is
through careful hand washing, in order
to prevent adults (health professionals
and relatives) from transmitting the
RSV to high-risk children. Thorough
hand washing, combined with the use
of disposable aprons, gloves, goggles
that protect both eyes and nose, can re-
duce by up to eight times the chances
of nosocomial infection44,47.
RESUMO RHCFAP/3041
BRICKS LF – Prevenção das infecções
pelo vírus sincicial respiratório.
Rev. Hosp. Clín. Fac. Med. S.
Paulo 56(3):79-90, 2001.
Em todo o mundo, o vírus sincicial
respiratório é o principal agente de in-
fecções agudas das vias aéreas baixas
em lactentes jovens e crianças. Aos
dois anos de idade, praticamente todas
as crianças já foram infectadas, e as
reinfeções são comuns, durante toda a
vida. Embora a maioria das infecções
seja leve, o vírus sincicial respiratório
pode causar doenças graves, especial-
mente em prematuros com displasia
broncopulmonar e, nos últimos anos,
tem sido identificado como causa im-
portante de infeções respiratórias em
pessoas que apresentam comprometi-
mento da imunidade ou outros proble-
mas médicos e em idosos hospitaliza-
dos. O impacto econômico dessas in-
fecções faz com que o desenvolvimen-
to de vacinas contra o vírus sincicial
respiratório seja altamente desejável,
entretanto, o insucesso da primeira va-
cina inativada contra esse agente difi-
cultou os progressos nesse campo e,
até o presente, não há nenhuma vaci-
na licenciada contra o vírus sincicial
respiratório. Nos últimos anos, entre-
tanto, o melhor entendimento sobre
imunologia e os mecanismos imuno-
patológicos envolvidos na resposta ao
vírus sincicial respiratório propiciaram
o desenvolvimento de novas estratégi-
as para a profilaxia ativa e passiva con-
tra essas infecções. Neste artigo, a au-
tora apresenta uma revisão sobre os
mais recentes avanços na prevenção
das infecções pelo vírus sincicial res-
piratório, tais como: uso de imunoglo-
bulina humana policlonal, anticorpos
monoclonais humanizados (ambos já
licenciados para uso em prematuros e
crianças com displasia bronco-
pulmonar) e o desenvolvimento de di-
ferentes vacinas que são potenciais
candidatas para imunização ativa con-
tra o vírus sincicial respiratório.
DESCRITORES: Vírus sincicial
respiratório. Anticorpos mono-
clonais. Imunoglobulina. Vacinas.
Imunização.
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